Ethical Considerations for Clinical Investigations of Medical Products Involving Children

On 26 September 2022 the FDA published the draft guidance for industry, sponsors and IRBs.

Clinical investigations in children are essential for obtaining data on the safety and effectiveness of drugs, biological products, and medical devices in children and to protect children from the risks associated with exposure to medical products that may be unsafe or ineffective. Children are a vulnerable population who cannot consent for themselves and who therefore are afforded additional safeguards when participating in a clinical investigation. Such safeguards are an essential requirement for the initiation and conduct of pediatric investigations as part of a medical product development program. This guidance describes the FDA’s current thinking regarding ethical considerations for clinical investigations of medical products in children.

Read more online 
Copyright Widler & Schiemann AG 2022. All Rights Reserved. /